Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears
Oruka Therapeutics, Inc.Oruka Therapeutics, Inc.(US:ORKA) Seeking Alpha·2026-01-06 02:51

Company Overview - Oruka Therapeutics, Inc. (ORKA) is an early-stage immunology company focused on developing therapies for psoriasis and related diseases [1] - The company's pipeline includes biologics ORKA-001 for plaque psoriasis (PsO) and ORKA-002 for PsO, psoriatic arthritis (PsA), and hidradenitis suppurativa (HS) [1] Product Pipeline - ORKA-001 and ORKA-002 are designed to have improved efficiency in treating their respective conditions [1]